Search Bar & Filters
Found 32 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Healthy Volunteer
Researchers are studying how eye movements during natural viewing might serve as markers for visuospatial difficulties in people who have had a stroke. This study aims to evaluate a new visual exploration training that uses an auditory biofeedback system to help improve these visuospatial problems. The study involves assessing eye movements, cognitive, motor, and functional status, along with brain imaging to understand the neurological basis of these eye movement patterns. Participants will be randomly assigned to one of two groups. One group will receive ten sessions of the new visual exploration training combined with standard neuropsychological rehabilitation at the IRCCS San Camillo hospital. This training guides eye movements toward important areas of images using real-time auditory feedback. The other group will receive only the standard neuropsychological rehabilitation. Both treatments are conducted in a clinical setting. During the study, participants will undergo assessments before and after rehabilitation, including eye movement recordings during free viewing, multiple neuropsychological tests, and brain imaging to measure structural and functional brain connectivity. The main outcomes are changes in eye movement patterns and improvements on various cognitive and visuospatial tests over 30 days. The study also monitors changes in brain connectivity to understand training effects.
Actively Recruiting
This research evaluates atezolizumab as an additional treatment for patients with malignant pleural mesothelioma who have undergone surgical removal of the tumor and show no visible remaining disease. This phase III trial compares atezolizumab to a placebo to assess how well it works in preventing disease recurrence. Patients are grouped based on tumor type and cancer stage to better understand treatment effects. Participants receive either atezolizumab at 1200 mg or a matching placebo every 21 days for up to 12 months, or until the disease returns, side effects become unacceptable, or the patient or doctor decide to stop treatment. The study uses a centralized system to randomly assign patients to one of these groups, ensuring a balanced comparison. Tumor samples are analyzed to study biological markers and gene expression. During the trial, patients undergo CT scans before starting treatment and then every 12 weeks for two years or until the disease progresses. Quality of life questionnaires are completed at the start and every 12 weeks. Researchers monitor safety, disease-free survival, and overall survival for up to a year. The study lasts several years, with follow-up assessments to understand treatment impact and patient well-being.
Actively Recruiting
Researchers are evaluating whether biofeedback treatment is more effective than standard verbal feedback training in helping people recover from dysphagia after a stroke. This multicenter randomized controlled study will enroll 100 patients who have had a stroke and experience swallowing difficulties. The goal is to compare the recovery of swallowing function between those receiving biofeedback and those receiving conventional therapy without visual feedback. Participants will undergo 20 sessions over 4 weeks, attending five one-hour sessions each week. In the biofeedback group, sensors will be placed on the mylohyoid muscle to provide real-time visual feedback on muscle activity during swallowing exercises. The control group will perform the same swallowing maneuvers but will receive only verbal feedback from a speech therapist. Both groups will use effortful swallow techniques, timing and coordination tasks, and the Masako maneuver during training. Before starting treatment, and at two follow-up pointsafter 4 weeks of therapy and again two months laterpatients will have clinical and instrumental evaluations including fibroendoscopy and several swallowing function scales. Researchers will measure swallowing efficacy, penetrationaspiration, pharyngeal residues, and quality of life related to swallowing. Data will be analyzed statistically to assess treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the Italian translation and validation of several clinical tools designed to assess swallowing and oral-motor function in patients with neurogenic dysphagia. These tools include the New Zealand Secretion Severity Scale for secretion management, the Reflex Cough Test from the cranial nerves assessment, the VASES scale used during fiberoptic endoscopic evaluation of swallowing, and the Drooling Severity Scale for saliva control. The study aims to provide reliable and standardized assessment instruments in Italian to help clinicians caring for people with neurological swallowing difficulties. The study involves no active treatment but focuses on validating these assessment tools in about 100 adult patients diagnosed with neurogenic dysphagia caused by various neurological conditions. Participants will undergo evaluations using the translated scales to test their internal consistency and inter-rater reliability. This observational study does not involve experimental interventions but uses diagnostic tests to collect data. Participants will be assessed once at baseline, with researchers measuring the consistency and reliability of the secretion and drooling scales as primary and secondary outcomes. The study includes clinical evaluations of swallowing and reflex cough function, with all assessments performed under stable medical conditions. The total duration of participation and follow-up is not specified, but the focus is on one-time validation measurements to support future clinical use of these tools.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of different doses of the drug AP31969 in reducing the burden of Atrial Fibrillation AF. The trial is a randomized Phase 2 study comparing several doses of AP31969 against a placebo in adults diagnosed with paroxysmal or persistent AF. Participants are carefully selected based on their AF history and burden, and the study monitors heart rhythm using implanted devices. Participants are assigned randomly to one of five groups receiving oral tablets twice daily for 12 weeks AP31969 at doses of 100 mg, 200 mg, 350 mg, or 500 mg added later, or a placebo without active properties. The study consists of three main periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days, totaling about 20 weeks. During the study, participants receive an implantable loop recorder to continuously monitor heart rhythm. Throughout the trial, participants undergo several assessments including blood and urine tests, electrocardiograms, and continuous rhythm monitoring via the loop recorder. The main outcome measured is the AF burden from weeks 2 to 12, with additional measures including the number of AF episodes, quality of life changes, and ventricular tachycardia episodes. Safety and adherence are closely monitored, and the follow-up period helps assess sustained effects and participant well-being after treatment ends.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
This research aims to develop and validate new tools to better assess language and communication abilities in people with aphasia, a condition caused by stroke that affects communication. Traditional assessments mainly focus on linguistic tasks, but they often overlook everyday communication skills, such as the use of gestures and factors like motivation and attention, which are important for setting personalized treatment goals. The study emphasizes the need for a more interactive and comprehensive approach that includes evaluating both the individuals and caregivers perceptions of communication effectiveness. The study involves an observational approach using a conversational method in speech-language rehabilitation. This method focuses on improving communication in real-life situations by practicing natural, interactive conversations that include verbal and non-verbal cues. Assessments will be conducted within these everyday contexts to help guide treatment planning more effectively. Participants will be evaluated over a 36-month period, with researchers measuring communicative efficacy as the primary outcome. The study will involve intensive neurorehabilitation patients or outpatients diagnosed with language and communication disorders after stroke. Various assessments, including questionnaires for participants and caregivers, will be used to understand communication skills, participation in daily life, and the use of gestures. This comprehensive evaluation aims to support better communication therapy planning and monitoring over time.
1-10 of 32
1